DDW Editor Reece Armstrong speaks to Francisca Neethling, Head of Biotherapeutic Services and Olivier Mirguet, Global Head of Chemistry, at Eurofins Discovery about the challenges of antibody drug conjugate drug discovery and development and how strategies have evolved over time for these important therapies. RA: What are some common challenges developers are facing with ADC development? FN & OM: Linker stability, achieving consistent drug-to-antibody ratio […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!